Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Democratic lawmaker presses antitrust enforcers on company ties, settlements

Published 01/07/2020, 07:38 PM
Updated 01/07/2020, 07:43 PM
Democratic lawmaker presses antitrust enforcers on company ties, settlements

WASHINGTON (Reuters) - The chair of the U.S. House of Representatives antitrust subcommittee pressed top regulators on Tuesday over merger decisions, including the Justice Department's approval of T-Mobile US Inc's (O:TMUS) proposed purchase of Sprint Corp (N:S).

Congressman David Cicilline raised antitrust questions as activists and Democratic presidential candidates are advocating for more aggressive enforcement of rules governing market concentration and corporate behavior.

In questions posted on a House website, Cicilline asked Makan Delrahim, head of the Justice Department's Antitrust Division, about text messages he had sent to Dish Network Corp (O:DISH) Chairman Charlie Ergen, who plans to buy assets that T-Mobile and Sprint would sell as part of an agreement to win federal approval for their deal.

The planned merger of the third and fourth largest wireless providers is being challenged by state attorneys general, led by California and New York. A trial in New York is underway.

Cicilline noted that Delrahim wrote to Ergen: "Today would be a good day to have your Senator friends contact the chairman," a reference to the chair of the Federal Communications Commission which has since approved the merger.

Cicilline asked Delrahim if he had offered lobbying advice to other merging companies and if it was appropriate to offer such advice.

Cicilline also pressed the antitrust chief on a report that the Trump administration has brought fewer criminal antitrust cases, essentially price-fixing, than any in 50 years. "Is it your view that market participants are no longer engaging in price-fixing at the rates they previously had?" Cicilline asked.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Cicilline asked Federal Trade Commission Chairman Joe Simons about the November approval of Bristol-Myers Squibb Co's (N:BMY) $74 billion purchase of Celgene (NASDAQ:CELG) on the condition it divest the drug Otezla.

Cicilline asked the agency whether its practice of focusing on product overlap is enough when analyzing this and other pharmaceutical mergers.

Cicilline also pressed Simons on the FTC's record $5 billion settlement with Facebook Inc (O:FB) for the social media company's violation of an earlier settlement with the agency. He cited criticism that Facebook Chief Executive Mark Zuckerberg was not held responsible for the order violations.

"What is the Commission doing to ensure that CEOs of large companies are held accountable when their companies violate antitrust law with the CEOs' knowledge or at his or her direction?," Cicilline asked.

An FTC spokesman declined to comment. A Justice Department spokesman did not immediately respond to a request for comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.